News

The study aims to investigate the efficacy and safety of AX200 as a treatment for acute ischemic stroke. The company anticipates to release initial findings of the AXIS

The submission of the NDA is based on the safety and efficacy data from a Phase 3 program consisting four double-blind placebo-controlled trials and two open-label long term

Medigent DIS of DeltaWare Systems, the Canadian business unit of Maximus, offers up-to-date profiles and information for improved health planning, evaluation and research. The Medigent DIS will be

Horizant is XenoPort’s first approved product. Horizant extended-release tablets are indicated for the management of postherpetic neuralgia (PHN) in adults patients. GSK holds commercialization rights and certain development

The results of the trial demonstrated that the DAC HYP showed reduction in annualized relapse rate by 54% when administered subcutaneously once every four weeks in 150mg dose

Bioservative is used to preserve microbiological samples for up to seven days and also delays the breakdown of DNA, RNA and peptides for up to 26 days. Bioservative

In the trial, the patients will smoke X-22 for a duration of six weeks time period with an aim to stop smoking by the end of 6 weeks.

Antares’ net loss was $1.554m, or $0.02 loss per diluted share, compared to net loss of $1.552m, or $0.02 loss per diluted share, for the same period in

CRPL is a subsidiary of TCG Lifesciences, a provider of drug discovery and development research services company. CTA CEO Marcus Clark said they expect that this collaboration will